<DOC>
	<DOC>NCT02005146</DOC>
	<brief_summary>Define the patients who lost HBsAg, studying the loss predictive factors and if there was suspension of treatment, study the evolution after that</brief_summary>
	<brief_title>Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<criteria>&gt;18 years old Chronic hepatitis B (HBeAg+ or HBeAg) HBsAg loss Treated with nucleoside/nucleotide analogues With or without previous interferon (IFN/PEGIFN) Patients with HBsAg loss after 2006 Immunocompetent patients Spontaneous HBsAg loss HBsAg loss while treatment in monotherapy or combinated with IFN or PEGIFN. Patients with hepatitis delta virus (HDV) coinfection. Patients with hepatitis C virus (HCV) coinfection. Patients with HIV coinfection. Patients with liver transplant. Patients with reactivated hepatitis B virus (HBV) by immunosuppressive treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Nucleoside/nucleotide</keyword>
	<keyword>HBsAg loss</keyword>
</DOC>